Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bay 946
2. Bay-946
3. Elmiron
4. Fibrocid
5. Hemoclar
6. Hoe 946
7. Hoe Bay 946
8. Hoe-946
9. Hoe-bay 946
10. Hoe-bay-946
11. Pentosan Polysulfate Sodium
12. Pentosan Polysulphate Sodium
13. Pentosan Sulfuric Polyester
14. Pentosane Sulfuric Polyester
15. Polyester, Pentosan Sulfuric
16. Polyester, Pentosane Sulfuric
17. Polypentose Sulfate
18. Polysulfate Sodium, Pentosan
19. Polysulfate, Pentosan
20. Polysulfated Xylan
21. Polysulphate Sodium, Pentosan
22. Pz 68
23. Pz-68
24. Pz68
25. Sodium, Pentosan Polysulfate
26. Sodium, Pentosan Polysulphate
27. Sp 54
28. Sp 54, Tavan
29. Sp-54
30. Sp54
31. Sp54, Xylan
32. Sulfate, Polypentose
33. Sulfate, Xylan
34. Sulfuric Polyester, Pentosan
35. Sulfuric Polyester, Pentosane
36. Tavan Sp 54
37. Xylan Sp54
38. Xylan Sulfate
39. Xylan, Polysulfated
1. 37300-21-3
2. Pentosan Sulfuric Polyester
3. Polypentose Sulfate
4. [(2r,3r,4s,5r)-2-hydroxy-5-[(2s,3r,4s,5r)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] Hydrogen Sulfate
5. Xylan, Hydrogen Sulfate
6. Unii-f59p8b75r4
7. Schembl157354
8. Chembl4073796
9. Chebi:184555
10. F59p8b75r4
11. Db00686
12. Q7165276
13. [(2r,3r,4s,5r)-2-hydroxy-5-[(2s,3r,4s,5r)-5-hydroxy-3,4-disulooxyoxan-2-yl]oxy-3-sulooxyoxan-4-yl] Hydrogen Sulate
14. [(2r,3r,4s,5r)-2-hydroxy-5-{[(2s,3r,4s,5r)-5-hydroxy-3,4-bis(sulfooxy)oxan-2-yl]oxy}-4-(sulfooxy)oxan-3-yl]oxidanesulfonic Acid
15. [(2s,3r,4s,5r)-5-hydroxy-2-{[(3r,4s,5r,6r)-6-hydroxy-4,5-bis(sulfooxy)oxan-3-yl]oxy}-4-(sulfooxy)oxan-3-yl]oxidanesulfonic Acid
16. 11096-31-4
Molecular Weight | 602.5 g/mol |
---|---|
Molecular Formula | C10H18O21S4 |
XLogP3 | -5.6 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 21 |
Rotatable Bond Count | 10 |
Exact Mass | 601.92234227 g/mol |
Monoisotopic Mass | 601.92234227 g/mol |
Topological Polar Surface Area | 356 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 1140 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Elmiron |
PubMed Health | Pentosan Polysulfate Sodium (By mouth) |
Drug Classes | Cystitis Agent, Urinary Stone Agent |
Drug Label | Pentosan polysulfate sodium is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water... |
Active Ingredient | Pentosan polysulfate sodium |
Dosage Form | Capsule |
Route | Oral |
Strength | 100mg |
Market Status | Prescription |
Company | Janssen Pharms |
2 of 2 | |
---|---|
Drug Name | Elmiron |
PubMed Health | Pentosan Polysulfate Sodium (By mouth) |
Drug Classes | Cystitis Agent, Urinary Stone Agent |
Drug Label | Pentosan polysulfate sodium is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water... |
Active Ingredient | Pentosan polysulfate sodium |
Dosage Form | Capsule |
Route | Oral |
Strength | 100mg |
Market Status | Prescription |
Company | Janssen Pharms |
For the relief of bladder pain or discomfort associated with interstitial cystitis.
FDA Label
Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects.
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Absorption
Slow
4.8 hours
Pentosan polysulfate is a polymer of xylose hydrogen sulfate and contains two sulfate groups per carbohydrate monomer. It binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors. It has been shown to interact also with the heparin-binding site of FGFR-1. It inhibits the growth of SW13 adrenocortical cells transfected with FGF-4 and tumorigenicity of MCF-7 breast carcinoma cells transfected with FGF-1 or FGF-4.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects. Clinical study has demonstrated that iPPS may slow the progression of osteoarthritis of the knee.
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects. Clinical study has demonstrated that iPPS may slow the progression of osteoarthritis of the knee.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2023
Details:
Pentosan Polysulfate Sodium (under the name Zilosul®) is used to treat osteoarthritis. iPPS impacted multiple biomarkers measured in the synovial fluid. Reductions in nerve growth factor (NGF) indicate iPPS mechanisms related to pain reduction.
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Brand Name: Zilosul
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial
Details : Pentosan Polysulfate Sodium (under the name Zilosul®) is used to treat osteoarthritis. iPPS impacted multiple biomarkers measured in the synovial fluid. Reductions in nerve growth factor (NGF) indicate iPPS mechanisms related to pain reduction.
Product Name : Zilosul
Product Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2022
Details:
Three of the four subjects included in Paradigm's open-label phase 2 trial of pentosan polysulfate sodium (PPS) in MPS-I have completed the 48-week study, with a 6-month treatment extension available.
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2022
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Three of the four subjects included in Paradigm's open-label phase 2 trial of pentosan polysulfate sodium (PPS) in MPS-I have completed the 48-week study, with a 6-month treatment extension available.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
August 12, 2022
Details:
Zilosul (pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs).
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Brand Name: Zilosul
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program
Details : Zilosul (pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs).
Product Name : Zilosul
Product Type : Small molecule
Upfront Cash : Not Applicable
April 12, 2022
Details:
The purpose of the study is to measure the change in pain and function with subcutaneous injections of Zilosul (Pentosan Polysulfate Sodium) compared with subcutaneous injections of placebo in participants with kOA pain.
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Rheumatology Brand Name: Zilosul
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The purpose of the study is to measure the change in pain and function with subcutaneous injections of Zilosul (Pentosan Polysulfate Sodium) compared with subcutaneous injections of placebo in participants with kOA pain.
Product Name : Zilosul
Product Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2022
Details:
In parallel, Paradigm is continuing Phase 3 study start-up preparation at sites in the US and Australia. Additional sites may be added in order to ensure completion of this pivotal study, within the planned commercialisation timelines.
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Brand Name: Zilosul
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Paradigm Biopharmaceuticals Receives US FDA Feedback on IND Application for PPS in Knee OA
Details : In parallel, Paradigm is continuing Phase 3 study start-up preparation at sites in the US and Australia. Additional sites may be added in order to ensure completion of this pivotal study, within the planned commercialisation timelines.
Product Name : Zilosul
Product Type : Small molecule
Upfront Cash : Not Applicable
May 25, 2021
Details:
Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for Zilosul® in Europe.
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Brand Name: Zilosul
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Paradigm Biopharmaceuticals has Clear Path Towards Zilosul® OA Phase 3 Clinical Trial and Product...
Details : Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for Zilosul®...
Product Name : Zilosul
Product Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2020
Details:
Proceeds will be applied to costs of the second phase 3 osteoarthritis (OA) clinical trial and leaves Paradigm fully-funded through to completion of this trial.
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bell Potter Securities
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 20, 2020
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bell Potter Securities
Deal Size : $35.0 million
Deal Type : Financing
Paradigm Biopharmaceuticals has Significant Clarity on Development Pathway for Zilusol
Details : Proceeds will be applied to costs of the second phase 3 osteoarthritis (OA) clinical trial and leaves Paradigm fully-funded through to completion of this trial.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
April 20, 2020
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Tavan-SP 54 Injection
Dosage Form : INJ
Dosage Strength : 100mg/ml
Packaging : 1X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : CARTROPHEN VET INJ.SC 100MG/ML
Dosage Form : SOLUTION
Dosage Strength : 100MG/ML
Packaging :
Approval Date :
Application Number : 2082101
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ELMIRON
Dosage Form : CAPSULE
Dosage Strength : 100MG
Packaging : 100
Approval Date :
Application Number : 2029448
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Spain
Brand Name :
Dosage Form : Cream
Dosage Strength : 1MG/G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Spain
Brand Name :
Dosage Form : Cream
Dosage Strength : 5MG/G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Switzerland
Brand Name : Elmiron
Dosage Form : Caps
Dosage Strength : 100mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : RX
Registration Country : USA
Brand Name : ELMIRON
Dosage Form : CAPSULE;ORAL
Dosage Strength : 100MG
Packaging :
Approval Date : 1996-09-26
Application Number : 20193
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Generic
Registration Country : Turkey
Brand Name :
Dosage Form : CAPSULE
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
Regulatory Info :
Registration Country : Italy
Brand Name : Fibrase
Dosage Form :
Dosage Strength : Pom Derm 40 G 1,5%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Fibrase
Dosage Form :
Dosage Strength : 50 Cps 50 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
ABOUT THIS PAGE
60
PharmaCompass offers a list of Pentosan Polysulfate Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pentosan Polysulfate Sodium manufacturer or Pentosan Polysulfate Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pentosan Polysulfate Sodium manufacturer or Pentosan Polysulfate Sodium supplier.
PharmaCompass also assists you with knowing the Pentosan Polysulfate Sodium API Price utilized in the formulation of products. Pentosan Polysulfate Sodium API Price is not always fixed or binding as the Pentosan Polysulfate Sodium Price is obtained through a variety of data sources. The Pentosan Polysulfate Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pentosan polysulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pentosan polysulfate, including repackagers and relabelers. The FDA regulates Pentosan polysulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pentosan polysulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pentosan polysulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pentosan polysulfate supplier is an individual or a company that provides Pentosan polysulfate active pharmaceutical ingredient (API) or Pentosan polysulfate finished formulations upon request. The Pentosan polysulfate suppliers may include Pentosan polysulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Pentosan polysulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pentosan polysulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Pentosan polysulfate active pharmaceutical ingredient (API) in detail. Different forms of Pentosan polysulfate DMFs exist exist since differing nations have different regulations, such as Pentosan polysulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pentosan polysulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Pentosan polysulfate USDMF includes data on Pentosan polysulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pentosan polysulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pentosan polysulfate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pentosan polysulfate Drug Master File in Korea (Pentosan polysulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pentosan polysulfate. The MFDS reviews the Pentosan polysulfate KDMF as part of the drug registration process and uses the information provided in the Pentosan polysulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pentosan polysulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pentosan polysulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pentosan polysulfate suppliers with KDMF on PharmaCompass.
A Pentosan polysulfate written confirmation (Pentosan polysulfate WC) is an official document issued by a regulatory agency to a Pentosan polysulfate manufacturer, verifying that the manufacturing facility of a Pentosan polysulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pentosan polysulfate APIs or Pentosan polysulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Pentosan polysulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Pentosan polysulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pentosan polysulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pentosan polysulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pentosan polysulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pentosan polysulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pentosan polysulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pentosan polysulfate suppliers with NDC on PharmaCompass.
Pentosan polysulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pentosan polysulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pentosan polysulfate GMP manufacturer or Pentosan polysulfate GMP API supplier for your needs.
A Pentosan polysulfate CoA (Certificate of Analysis) is a formal document that attests to Pentosan polysulfate's compliance with Pentosan polysulfate specifications and serves as a tool for batch-level quality control.
Pentosan polysulfate CoA mostly includes findings from lab analyses of a specific batch. For each Pentosan polysulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pentosan polysulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Pentosan polysulfate EP), Pentosan polysulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pentosan polysulfate USP).